Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of BI 1323495 (Fed vs Fasted) in Healthy Males
NCT03802331Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2019
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of BI 1323495 in chronic obstructive pulmonary disease (COPD) and bronchiectasis (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve of BI 1323495 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point and Maximum Measured Concentration of BI 1323495 in Plasma. Started Jan 2019; status: completed.
02
Drugs
BI 1323495
03
Conditions
chronic obstructive pulmonary disease (COPD)bronchiectasis
Beyond the preview
Go deeper on NCT03802331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03802331.